11/21 Exact Sciences, We Bid You Farewell •EXAS share price more than quadrupled since the beginning of 2017. Time to take profit. •EXAS has generated losses since its inception and expects to continue to incur losses in the near future. •EXAS is currently valued at more than 27 times price-to-2017-sales, rather pricey for the molecular diagnostics industry sector. https://seekingalpha.com/article/4126796-sold-cologuard-maker-exact-sciences?auth_param=1vat:1d18h27:bb41b36a79b3544547eed9f8b9a0cbb6&uprof=51#alt2